Abdul-Hamid Bazarbachi,Divaya Bhutani,Michael Sang Hughes et al.
Abdul-Hamid Bazarbachi et al.
The treatment landscape for multiple myeloma is rapidly evolving, driven by T-cell-mediated tumor responses through CAR T-cell therapies and bispecific antibodies. Since KarMMa and CARTITUDE-1 established the activity of idecabtagene vicleu...
Differences between Physicians' and Nurses' Perspectives in Defining Core Nursing-Sensitive Outcomes in Adult HSCT and CAR-T Therapy: An Interdisciplinary Italian Delphi Consensus [0.03%]
意大利成人HSCT和CAR-T治疗医师与护士核心敏感护理结果定义视角的差异：跨学科德尔菲共识研究
Marco Cioce,Simona Sica,Sarah Jayne Liptrott et al.
Marco Cioce et al.
Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience [0.03%]
丹唑治疗造血干细胞移植后移植物功能不良的疗效分析：单中心经验报告
Fabio Serpenti,Nicole Galli,Francesca Cavallaro et al.
Fabio Serpenti et al.
Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience [0.03%]
倍林妥莫双抗自体T细胞疗法门诊给药可行性的范德堡大学医学中心经验及对医疗保健利用成本的影响
Ihunayachi Ohuabunwa,Bhagirathbhai Dholaria,Megan Wanca et al.
Ihunayachi Ohuabunwa et al.
Identification and management of the backup donor: recommendations from the World Marrow Donor Association [0.03%]
世界骨髓捐献者协会对备用捐献者识别和管理的建议
Valerie Greco-Stewart,Sigal Manor,Simona Pollichieni et al.
Valerie Greco-Stewart et al.
Treosulfan-based double-alkylator conditioning in myelofibrosis: An Italian retrospective multicenter analysis [0.03%]
基于 Treosulfan 的双重预处理方案治疗骨髓纤维化：一项意大利多中心回顾性分析研究
Nicola Polverelli,Annalisa Pitino,Irene Defrancesco et al.
Nicola Polverelli et al.
Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphoma [0.03%]
复发/难治型套细胞淋巴瘤CAR-T治疗的现实世界适用性、使用情况及障碍因素分析
Robert Puckrin,Vladimir Sapon-Cousineau,Anthea Peters et al.
Robert Puckrin et al.
Integrating palliative care into hematopoietic cell transplantation and cellular therapy training [0.03%]
姑息治疗在造血细胞移植和细胞疗法培训中的应用整合
Esra Gulderen,Azada Ibrahimova,Alex Rampotas et al.
Esra Gulderen et al.
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm [0.03%]
欧洲血液和骨髓移植协会慢性恶性肿瘤工作组有关移植物抗宿主病患者异基因造血细胞移植的欧洲调查：jak抑制剂、脾大管理及新型药物在移植方案中的应用的“真实世界”经验聚焦
Alexandros Rampotas,Jose Maria Aspa-Cilleruelo,Linda Koster et al.
Alexandros Rampotas et al.
Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only potentially curative option for patients with myelofibrosis (MF), yet the integration of JAK inhibitors (JAKi) and novel agents into transplant pathways has created ...
The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations [0.03%]
DNMT3A基因突变对核型及合并其他基因突变对AML患者allo-HSCT后预后的累积影响分析
Iman Abou Dalle,Jacques-Emmanuel Galimard,Xavier Poire et al.
Iman Abou Dalle et al.
Mutations in the DNMT3A gene are not yet classified as a distinct prognostic group in the latest European Leukemia Net (ELN) 2022 genetic risk classification of AML. We analyzed 1888 adult AML patients with ELN 2022 intermediate- or poor-ri...